Pfizer Corporation

Thomas Allen Chappie

Patrick Robert Verhoest

Christopher John Helal

Nandini Chaturbhai Patel

Simone Sciabola

Travis T Wager

Matthew Merrill Hayward

Erik Alphie LaChapelle

Bethany Lyn Kormos

Joseph Michael Young

John Michael Humphrey

Jaclyn Louise Henderson

Jamison Bryce Tuttle

Erik Alphie Lachapelle

Martin Youngjin Pettersson

Antonia Friederike Stepan

Paul Galatsis

Michelle Renee Garnsey

Ramalakshmi Yegna Chandrasekaran

Ravi G Kurumbail

Luis Angel Martinez-Alsina

Joseph Walter Tucker

Eddie Yang

Michael Aaron Brodney

Brian Thomas O'Neill

Jotham Wadsworth Coe

Arthur A Nagel

Spiros Liras

Yuan Zhang

Joseph Scott Warmus

Karen Jean Coffman

Matthew Richard Reese

Martin Patrick Allen

Jinshan Michael Chen

Susan Beth Sobolov-Jaynes

Lawrence Albert Vincent

Jianhua Huang

William Michael Whalen

Eric Platt Arnold

Jamison Byrce Tuttle

Colin Richard Rose

Travis T Wagner

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R, R, R, R, R, Rand n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.

Tricyclic compounds and their use as phosphodiesterase inhibitors

The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts thereof wherein the variables R, R, R, R, R, a and A are as defined herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D3-mediated (or D3-associated) disorders including, e.g., substance addiction, substance abuse, schizophrenia (e.g., its cognitive symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD or PD), Parkinson's disease, mania, anxiety, impulse control disorders, sexual disorders and depression. 

6,7,8,9-tetrahydro-5H-pyrido[2,3-d]azepine dopamine D3 ligands

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Cyclic substituted imidazo[4,5-c]quinoline derivatives

The present invention is directed to PDE4B inhibitors of Formula I: (I) or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds. 

6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, R, and b are as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

Imidazopyridazine compounds

The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents R, R, R, and Rare as defined herein. The invention is also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, and methods of preparing the compounds.

The present invention is directed to pyrazolopyrimine compounds or pharmaceutically acceptable salts which are inhibitors of PDE4 isozymes, especially with a binding affinity for PDE4B isoform, and compositions thereof.

Pyrazolopyrimidine compounds

The present invention is directed to compounds of formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein.

Azabenzimidazole compounds

The present invention is directed to a new class of triazine derivatives as described by formula I below in which A, X, R, R, R, and Rare as defined herein and to the use of the compounds as PDE10 inhibitors. 

Triazine derivatives

The present invention relates to compounds of the Formula 

Imidazo[5,1-f][1,2,4]triazines for the treatment of neurological disorders

Growing community of inventors

Carlisle, MA, United States of America

Thomas Allen Chappie